血脂代谢异常与乳腺癌预后关系的研究进展
摘要
方案，包括影像学检查、术前辅助疗法及手术已经比较成熟了，但导致这种疾病的具体原因还未完全明晰。最近几
年，血脂紊乱与乳腺癌的关系已成为研究焦点，大量循证医学证据表明，血脂状况与体内雌激素的产生密切相关。
人体合成雌激素的一个重要方式就是把胆固醇转化过去。而当血液中的胆固醇、甘油三酯等血脂指标出现异常时，
可能会增加雌激素合成所需的前体物质以及一种关键酶（芳香化酶）的活性，进而提升雌激素合成效率，最终可能
促使乳腺正常细胞转变成癌细胞。这篇综述通过梳理国内外相关研究，探讨血脂水平如何影响乳腺癌的发生和进展，
旨在剖析乳腺癌的发病机制，并为该病的预防、诊断及治疗探索新的方向。
关键词
全文:
PDF参考
[1]Qi J, Li M, Wang L, et al. National and subnational
trends in cancer burden in China, 2005-20: an analysis of
national mortality surveillance data. Lancet Public Health.
2023;8(12):e943-e955.
[2]Han B, Zheng R, Zeng H, et al. Cancer incidence
and mortality in China, 2022. J Natl Cancer Cent.
2024;4(1):47-53. Published 2024 Feb 2.
[3]谭 桂 军.肥 胖 的 治 疗[J].开 卷 有 益-求 医 问 药，
2022（08）：51-52.
[4]赵崇如，熊铭琛，张奇，等.脂肪细胞在乳腺癌
发展及治疗中的相关作用机制研究进展[J].中华整形外科
杂志，2021，37（10）：1186-1191.
[5]王欣如.血脂及影像脂肪定量与乳腺癌组织学分
型的相关性研究[D].南京中医药大学，2023.
[6]Løyland B, Sandbekken IH, Grov EK, Utne I. Causes
and Risk Factors of Breast Cancer, What Do We Know for
Sure? An Evidence Synthesis of Systematic Reviews and
Meta-Analyses. Cancers (Basel). 2024;16(8):1583. Published
2024 Apr 20.
[7]Giacomini I, Gianfanti F, Desbats MA, et al.
Cholesterol Metabolic Reprogramming in Cancer and Its
Pharmacological Modulation as Therapeutic Strategy. Front
Oncol. 2021;11:682911. Published 2021 May 24.
[8]Chowdhury FA, Islam MF, Prova MT, et al. Association
of hyperlipidemia with breast cancer in Bangladeshi women.
Lipids Health Dis. 2021;20(1):52. Published 2021 May 22.
[9]Nelson ER, Chang CY, McDonnell DP. Cholesterol
and breast cancer pathophysiology. Trends Endocrinol Metab.
2014;25(12):649-655. doi:10.1016/j.tem.2014.10.001.
[10]Nelson ER, Wardell SE, Jasper JS, et al. 27-
Hydroxycholesterol links hypercholesterolemia and breast
cancer pathophysiology. Science. 2013;342(6162):1094-1098.
[11]Marwarha G, Raza S, Hammer K, Ghribi O.
27-hydroxycholesterol: A novel player in molecular
carcinogenesis of breast and prostate cancer. Chem Phys
Lipids. 2017;207(Pt B):108-126.
[12]McDonnell DP, Park S, Goulet MT, et al. Obesity,
cholesterol metabolism, and breast cancer pathogenesis.
Cancer Res. 2014;74(18):4976-4982.
[13]Cedó L, Reddy ST, Mato E, Blanco-Vaca F,
Escolà-Gil JC. HDL and LDL: Potential New Players in
Breast Cancer Development. J Clin Med. 2019;8(6):853.
Published 2019 Jun 14.
[14]Blücher C, Stadler SC. Obesity and Breast Cancer:
Current Insights on the Role of Fatty Acids and Lipid
Metabolism in Promoting Breast Cancer Growth and
Progression. Front Endocrinol (Lausanne). 2017;8:293.
Published 2017 Oct 30.
[15]Moksud N, Loo LWM, Yang J, et al. Cholesterol
lowering drug use and breast cancer survival: the Multiethnic
Cohort Study. Breast Cancer Res Treat. 2021;190(1):165-173.
[16]Wu J, Lei X, Pan X, Zeng X, Li W. Association
between serum lipids and breast cancer risk in premenopausal
women: systematic review and meta-analysis. J Int Med Res.
2021;49(11):3000605211061033.
[17]Wei Y, Huang Y, Yang W, et al. The significances
and clinical implications of cholesterol components in human
breast cancer. Sci Prog. 2021;104(3):368504211028395.
[18]Lofterød T, Mortensen ES, Nalwoga H, et al. Impact
of pre-diagnostic triglycerides and HDL-cholesterol on breast
cancer recurrence and survival by breast cancer subtypes. BMC
Cancer. 2018;18(1):654. Published 2018 Jun 15.
[19]Gupta A, Saraiya V, Deveaux A, et al. Association
of lipid profile biomarkers with breast cancer by
molecular subtype: analysis of the MEND study. Sci Rep.
63
现代医学前沿 | 第4卷/第4期
Advances in Modern Medical
2022;12(1):10631. Published 2022 Jun 23.
[20]His M, Dartois L, Fagherazzi G, et al. Associations
between serum lipids and breast cancer incidence and survival
in the E3N prospective cohort study. Cancer Causes Control.
2017;28(1):77-88.
[21]Pellon-Maison M, Montanaro MA, Lacunza E,
et al. Glycerol-3-phosphate acyltranferase-2 behaves as a
cancer testis gene and promotes growth and tumorigenicity
of the breast cancer MDA-MB-231 cell line. PLoS One.
2014;9(6):e100896. Published 2014 Jun 26.
[22]Rajagopal G, Suresh V, Sachan A. High-density
lipoprotein cholesterol: How High. Indian J Endocrinol
Metab. 2012;16(Suppl 2):S236-S238.
[23]Han YH, Onufer EJ, Huang LH, et al. Enterically
derived high-density lipoprotein restrains liver injury through
the portal vein. Science. 2021;373(6553):eabe6729.
[24]Zabłocka-Słowińska K, Płaczkowska S, Skórska
K, et al. Oxidative stress in lung cancer patients is associated
with altered serum markers of lipid metabolism. PLoS One.
2019;14(4):e0215246. Published 2019 Apr 11.
[25]Li X, Liu ZL, Wu YT, et al. Status of lipid and
lipoprotein in female breast cancer patients at initial diagnosis
and during chemotherapy. Lipids Health Dis. 2018;17(1):91.
Published 2018 Apr 20.
[26]DeRouen MC, Yang J, Li Y, et al. Circulating 27-
hydroxycholesterol, lipids, and steroid hormones in breast
cancer risk: a nested case-control study of the Multiethnic
Cohort Study. Breast Cancer Res. 2023;25(1):95. Published
2023 Aug 14.
[27]Johnson KE, Siewert KM, Klarin D, et al. The
relationship between circulating lipids and breast cancer
risk: A Mendelian randomization study. PLoS Med.
2020;17(9):e1003302. Published 2020 Sep 11.
[28]Deng CF, Zhu N, Zhao TJ, et al. Involvement
of LDL and ox-LDL in Cancer Development and Its
Therapeutical Potential. Front Oncol. 2022;12:803473.
Published 2022 Feb 16.
[29]Nowak C, Ärnlöv J. A Mendelian randomization
study of the effects of blood lipids on breast cancer risk. Nat
Commun. 2018;9(1):3957. Published 2018 Sep 27.
[30]Li M, Lu J, Fu J, et al. The association and joint
effect of serum cholesterol, glycemic status with the risk of
incident cancer among middle-aged and elderly population in
china cardiometabolic disease and cancer cohort (4C)-study. Am
J Cancer Res. 2020;10(3):975-986. Published 2020 Mar 1.
[31]AiErken N, Shao N, Liu Y, et al. Effect of Lipid
Levels on Tumor-Infiltrating Lymphocytes and Prognosis
in Patients with Triple-Negative Breast Cancer. Breast Care
(Basel). 2023;18(5):390-398.
[32]Berry DA, Cronin KA, Plevritis SK, et al. Effect
of screening and adjuvant therapy on mortality from breast
cancer. N Engl J Med. 2005;353(17):1784-1792.
[33]杨莉萍，侯敢.乳腺癌患者手术前后Lp（a）、脂
联素和TNF-α水平观察与分析[J].数理医药学杂志，
2006（05）：492-493.
[34]Gaibar M, Fernández G, Romero-Lorca A, et al.
Tamoxifen therapy in breast cancer: do apolipoprotein E
genotype and menopausal state affect plasma lipid changes
induced by the drug?. Int J Biol Markers. 2013;28(4):e371-
e376. Published 2013 Dec 17.
[35]Chi F, Wu R, Zeng Y, Xing R, Liu Y, Xu Z.
Effects of toremifene versus tamoxifen on breast cancer
patients: a meta-analysis. Breast Cancer. 2013;20(2):111-122.
[36]Hozumi Y, Suemasu K, Takei H, et al. The effect
of exemestane, anastrozole, and tamoxifen on lipid profiles
in Japanese postmenopausal early breast cancer patients:
final results of National Surgical Adjuvant Study BC 04, the
TEAM Japan sub-study. Ann Oncol. 2011;22(8):1777-1782.
[37]Wang K, Shen L, Tian W, Zhang S. Comparison of
changes in lipid profiles of premenopausal women with earlystage breast cancer treated with different endocrine therapies.
Sci Rep. 2022;12(1):22650.
[38]Kalábová H, Melichar B, Ungermann L, et al.
Intima-media thickness, myocardial perfusion and laboratory
risk factors of atherosclerosis in patients with breast cancer
treated with anthracycline-based chemotherapy. Med Oncol.
2011;28(4):1281-1287.
[39]Panis C, Binato R, Correa S, et al. Short infusion of
paclitaxel imbalances plasmatic lipid metabolism and correlates
with cardiac markers of acute damage in patients with breast
cancer. Cancer Chemother Pharmacol. 2017;80(3):469-478.
作者贡献：
张哲：文献查阅，文章撰写。
王相涵：文献查阅
刘素坤：文章修改
Refbacks
- 当前没有refback。
